Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Merck is stopping a Phase 3 trial of its pulmonary arterial hypertension treatment Winrevair almost a year early following positive interim data, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Clinical Challenges: Test Your Knowledge of HIV

A MedPage Today Clinical Challenges series on HIV looked at long-acting antiretroviral therapy (ART), HIV care during the COVID pandemic, and efforts to destigmatize HIV

October 31, 2023

invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma – Biotech Investments

EQS-News: invIOs GmbH / Key word(s): Miscellaneous/Patent invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma 17.07.2024 / 10:00 CET/CEST

July 18, 2024

Nxera wins $35m after Phase II schizophrenia trial success – Pharmaceutical Technology

Schizophrenia patients can suffer from both positive and negative symptoms. Credit: Drawlab19 via Shutterstock. Japanese biopharma Nxera Pharma has secured $35m in milestone payments from

September 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.